WO2026051929 - COMPOUND ACTING AS WRN INHIBITOR AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2026/051929
Publication Date
12.03.2026
International Application No.
PCT/CN2025/118577
International Filing Date
03.09.2025
Title **
[English]
COMPOUND ACTING AS WRN INHIBITOR AND USE THEREOF
[French]
COMPOSÉ AGISSANT EN TANT QU'INHIBITEUR DE WRN ET SON UTILISATION
[Chinese]
作为WRN抑制剂的化合物及其应用
Applicants **
NANJING SANHOME PHARMACEUTICAL CO., LTD.
Inventors
YU, Zhuangzhuang
QUAN, Xu
ZHANG, Xiaomeng
BAI, Lei
KUANG, Xiuping
Priority Data
202411235356.3
04.09.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1665 | |
| EPO | Filing, Examination, Granting | 11917 | |
| Japan | Filing, Examination, Granting | 2023 | |
| South Korea | Filing, Examination, Granting | 1783 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
22,128
Contact Us
Abstract[English]
Provided are a class of compounds acting as WRN inhibitors and a use thereof, in the field of medicinal chemistry. Specifically, provided are compounds represented by formulas (I) and (II), or pharmaceutically acceptable salts, isomers, solvates, crystals or prodrugs thereof, as well as preparation methods therefor, pharmaceutical compositions containing said compounds, and a use of the compounds or compositions for treating WRN-related diseases.[French]
L'invention concerne une classe de composés agissant en tant qu'inhibiteurs de WRN et leur utilisation, dans le domaine de la chimie médicale. Plus particulièrement, l'invention concerne des composés représentés par les formules (I) et (II), ou des sels, isomères, solvates, cristaux ou promédicaments pharmaceutiquement acceptables de ceux-ci, ainsi que des procédés de préparation associés, des compositions pharmaceutiques contenant lesdits composés, et une utilisation des composés ou des compositions pour le traitement de maladies associées à WRN.[Chinese]
为医药化学领域提供一类作为WRN抑制剂的化合物及其应用，具体地，提供式(I)和(II)所示的化合物或其药学上可接受的盐、异构体、溶剂化物、结晶或前药，它们的制备方法以及含有这些化合物的药物组合物和这些化合物或组合物用于治疗与WRN相关的疾病的用途。